OncoMatch/Clinical Trials/NCT07294508
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Is NCT07294508 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including HLX87 + HLX22 and HLX87 + Pertuzumab for her2 + breast cancer.
Treatment: HLX87 + HLX22 · HLX87 + Pertuzumab · T-Dxd + Pertuzumab · THP — The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 3+ or IHC 2+ and ISH+)
HER2-positive as determined by the central laboratory, defined as IHC 3+, or IHC 2+ and ISH+.
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: HER2-targeted therapy
No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer
Cannot have received: chemotherapy
No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer
Cannot have received: antibody-drug conjugate
Prior treatment with ADCs including exatecan derivatives that contain topoisomerase I inhibitors.
Cannot have received: anthracycline (doxorubicin)
Exception: Previous use of doxorubicin with a concentration of > 360 mg/m2 (or equivalent)
Previous use of doxorubicin with a concentration of > 360 mg/m2 (or equivalent).
Lab requirements
Blood counts
Adequate organ functions
Kidney function
Adequate organ functions
Liver function
Adequate organ functions
Adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify